RxDoctor Payments Data

Ryan Hamby, DO

Gastroenterology · Wyoming, MINPI 1871793216

Payments from drug & device makers

$1,374in general payments, 2019–2025

Across 47 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$780
  • Covidien LP$238
  • Boston Scientific$156
  • Johnson & Johnson$84
  • Takeda Pharmaceuticals U.S.A., Inc.$41
  • Sanofi$29
  • plus $45 from 2 others

What the payments were for

  • Food & beverage$1,24891%
  • Education$1259%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,374 in reported general payments places this provider in the 40th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$55,230
Medicare patients
244
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab38$410,566
XifaxanRifaximin23$71,098
LinzessLinaclotide38$33,695
ViberziEluxadoline13$21,340
VemlidyTenofovir Alafenamide14$18,886
Mesalamine14$12,260
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg374$9,245
MotegrityPrucalopride Succinate12$8,312
MovantikNaloxegol Oxalate13$5,029
SutabSod Sulf/Pot Chloride/Mag Sulf30$4,857
Omeprazole146$3,554
Azathioprine25$2,832
Budesonide DrBudesonide16$1,886
Pantoprazole Sodium68$1,704
Dicyclomine Hcl42$1,286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Viberzi$780$55,03551 claims
GileadVemlidy$19$18,88614 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$41$8,31212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Wyoming

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →